Some studies have associated NPM1-mutated AML with CD117+ blasts with increased expression of CD33 and/or CD123 and decreased expression or absence of CD13, HLA-DR, CD15, and CD64, along with CD34 [80,81]. This evidence concerns the gene FCGR1A and acute myeloid leukemia.